Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
EPS (Diluted)
Mayne Pharma Group Ltd
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
EPS (Diluted)
AU$1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
16%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
EPS (Diluted)
AU$1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
111%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
0%
|
CAGR 5-Years
20%
|
CAGR 10-Years
27%
|
|
Probiotec Ltd
ASX:PBP
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
10%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's EPS (Diluted)?
EPS (Diluted)
1.4
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's EPS (Diluted) amounts to 1.4 AUD.